Intrauterine Infusion of Leukocyte-Poor Platelet-Rich Plasma Is an Effective Therapeutic Protocol for Patients with Recurrent Implantation Failure: A Retrospective Cohort Study

The clinical application of autologous leukocyte-poor platelet-rich plasma (LP-PRP) in patients with recurrent implantation failure (RIF) is rare. This retrospective observational cohort study aimed to evaluate the efficacy of LP-PRP intrauterine infusion in patients with RIF. Patients with RIF undergoing frozen embryo transfer (FET) from January 2019 to December 2021 ( = 118) were enrolled, with those undergoing LP-PRP intrauterine infusion as the PRP group ( = 64), and those receiving no LP-PRP treatment as the control group ( = 54). The beta-human chorionic gonadotropin (β-hCG)-positive rate, clinical pregnancy rate (CPR), live birth rate (LBR), and miscarriage rate (MR) per ET cycle were compared. The β-hCG-positive rate (57.8% vs. 38.9%, = 0.041), CPR (45.3% vs. 24.5%, = 0.022), and LBR per ET cycle (42.2% vs. 18.5%, = 0.009) were higher in the PRP group than in the control group, and the three variables (62.5% vs. 41.2%, = 0.040, 47.5% vs. 23.5%, = 0.033, and 47.5% vs. 20.6%, = 0.027) in the PRP group transferred with the were also higher than those in the control group. The MR was similar in all groups. The LP-PRP treatment could improve the β-hCG-positive rate, CPR, and LBR in RIF patients undergoing FET cycles.